Bladder Cancer Clinical Trial

Phase II Study of Bladder-Sparing Chemoradiation with Durvalumab in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)

 

EA8185 represents a joint scientific collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and NRG Oncology, with ECOG-ACRIN as the lead group for trial conduct.

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.

    • Study Summary for Patients: study objectives, eligibility criteria, and a simplified schema in lay language to provide a more visual description of the trial to patients

Recruitment/Awareness Promotional Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.

    • Patient-Directed Communications Plan: patient-friendly language, images, and sample social media posts for use by participating sites and patient advocates to promote awareness of and recruitment to EA8185/INSPIRE

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT04216290

Return to Home Page | Review Other Active Trials